In the past year, Dr. Vachal spoke with 30 congressional offices about Merck’s pioneering work on engineered cyclic peptides. Using 3D printed models, he demonstrated the complex chemistry and unique potential of these molecules, which have the potential to revolutionize clinical outcomes and patient access.
Petr Vachal, Ph.D.
